Cancer immunotherapy: Progress and challenges in the clinical setting.

European journal of immunology

Volumn 41, Issue 6, 2011, Pages 1510-1515

  Zarour, Hassane M ^a   Ferrone, Soldano ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG DEVELOPMENT; DRUG EFFECT; GENETIC ENGINEERING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SURVIVOR; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG DISCOVERY; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; SURVIVORS; T-LYMPHOCYTES;

EID: 80051935724     PISSN: None     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201190035     Document Type: Review

References (0)